Sources: Global Glucagon-like Peptide 1 (GLP-1) Market Analysis Report 2023: Potential Clinical Application of GLP-1 Receptor Agonists For the Treatment of NASH Gaining Momentum. GlobeNewswire, January 30, 2023

Stomach-related symptoms of Ozempic: Ileus (the bowel muscles stop working and do not move food through the system) Acute gallbladder disease Gallbladder problems Pancreatitis Intestinal obstruction Nausea Vomiting Diarrhea Source: FDA King Law Criteria To File An Ozempic Lawsuit King Laws eligibility criteria for filing an Ozempic lawsuit include the following: The client used Ozempic or another GLP-1 drug The client developed a complication that research has shown may be a result of Ozempic use The client has seen a medical professional to diagnose and treat their injury The clients doctors have formally diagnosed them with a condition that lawsuits allege is related to Ozempic use The client had to undergo treatment to address the condition These criteria have changed over time as King Law has learned more about the complications that Ozempic patients might have experienced

Some people alternate between the two medications over time, using semaglutide for maintenance and tirzepatide for periods when they need additional weight loss
Pelicano H, Carney D, Huang P
How can Semaglutide be compared with related catalog records
The latest clinical trial, OASIS 4, has shown that oral semaglutide at a maximum daily dose of 25 mg can result in an average weight loss of 16.6% over 64 weeks